Investigational Drug Information for ALXN2050
✉ Email this page to a colleague
What is the development status for investigational drug ALXN2050?
ALXN2050 is an investigational drug.
There have been 17 clinical trials for ALXN2050.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are Glomerulonephritis, IGA, Renal Insufficiency, and Myasthenia Gravis. The leading clinical trial sponsors are Alexion Pharmaceuticals, Celerion, and Achillion, a wholly owned subsidiary of Alexion.
There are three US patents protecting this investigational drug and thirty-three international patents.
Summary for ALXN2050
| US Patents | 3 |
| International Patents | 33 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-11-01) |
| Vendors | 18 |
Recent Clinical Trials for ALXN2050
| Title | Sponsor | Phase |
|---|---|---|
| Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine | Alexion Pharmaceuticals, Inc. | Phase 1 |
| A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants | Alexion | Phase 1 |
| Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | Parexel | Phase 1 |
Clinical Trial Summary for ALXN2050
Top disease conditions for ALXN2050
Top clinical trial sponsors for ALXN2050
US Patents for ALXN2050
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ALXN2050 | ⤷ Subscribe | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Subscribe |
| ALXN2050 | ⤷ Subscribe | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Subscribe |
| ALXN2050 | ⤷ Subscribe | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ALXN2050
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ALXN2050 | Argentina | AR106018 | 2035-08-26 | ⤷ Subscribe |
| ALXN2050 | Australia | AU2016311425 | 2035-08-26 | ⤷ Subscribe |
| ALXN2050 | Australia | AU2021202728 | 2035-08-26 | ⤷ Subscribe |
| ALXN2050 | Canada | CA2996415 | 2035-08-26 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
